Phase

Intrinsic Imaging Awarded International Four Year Phase II Trial for New …
Intrinsic Imaging, an FDA audited, ISO 9001, ISO 13485 and ISO 22301 certified imaging core lab, announced today that it has been awarded a global Phase II clinical trial designed to investigate the safety and efficacy of a new pharmaceutical compound ... [...]
2
Like
Save
Transition begins patient dosing in phase 2 study of SARM drug candidate TT701
The phase 2 study will evaluate the efficacy and safety of TT701 in improving the symptoms of androgen deficiency (sexual symptoms, fatigue/low vitality, and physical dysfunction) in men with prostate cancer who have undergone radical prostatectomy for ... [...]
4
Like
Save
Transition Therapeutics Shares Add 2%; Doses First Patient in Phase 2 Study in …
... higher 2.5% on Tuesday after the company said it has dosed the first patient in a phase 2 study of TT701 in improving the symptoms of androgen deficiency — sexual symptoms, fatigue/low vitality, and physical dysfunction — in men with prostate cancer. [...]
2
Like
Save
OncBioMune Enters Joint Venture, Preparation for Phase 2 Trial of Novel Cancer …
During the process of formally creating the JV, OncBioMune and Vitel are working collaboratively to design a Phase 2 clinical trial of ProscaVax, OncBioMune's novel vaccine for the treatment of prostate cancer. The protocol is being developed and the ... [...]
5
Like
Save
Phase 3 Trial Shows Rheumatoid Arthritis Symptoms Significantly Improved with …
The RA-BEACON (ClinicalTrials.gov Identifier: NCT01721044) study enrolled 527 patients who had previously failed at least one anti-TNF therapy, and included a high percentage of patients (199) who had also received prior treatment with one or several ... [...]
2
Like
Save
CymaBay Therapeutics Announces Acceptance of Arhalofenate Phase 2b Gout Study …
/EIN News/ -- NEWARK, Calif., March 28, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), today announced the online publication of its Phase 2b study of arhalofenate, a novel dual-acting product candidate for the treatment of ... [...]
7
Like
Save
OncoMed Initiates Phase 1b Immuno-Oncology Combination Clinical Trial For …
Once an optimal combination dose is established, three expansion study cohorts will be enrolled in non-small cell lung cancer (NSCLC), anti-PD1 refractory solid tumors and castrate-resistant prostate cancer. ... To the extent that statements contained ... [...]
4
Like
Save
Vitae Pharma Reports Positive Phase 2a Results For Psoriasis Treatment VTP …
“While the autoimmune market is currently dominated by injectable antibody therapy, we believe VTP-43742 has the potential to expand utilization of oral therapy in a variety of autoimmune disorders, such as psoriasis, psoriatic arthritis, rheumatoid ... [...]
7
Like
Save
OPKO Health Announces Dosing of First Subject in Phase 1 Clinical Study of a …
... Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 420-person sales force to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros®1 in-office ... [...]
1
Like
Save
Phase 3 Trial Results Look Promising for Rheumatoid Arthritis Treatment Sarilumab
“Despite the availability of a wide range of treatment options, we believe that new therapies are needed to further address unmet needs of rheumatoid arthritis patients,” said Dr. Simon Cooper, MBBS vice president and global project head of immunology ... [...]
2
Like
Save
Nature Cell begins U.S. phase II trials of arthritis stem cell therapy
Dubbed “Joint Stem,” Nature Cell's new therapy uses about 10 grams of fat tissue extracted from a given patient's glenoid cavity to incubate some 100 million mesenchymal stem cells, which are later compressed into a 3 cubic-centimeters injection. [...]
3
Like
Save
Oncothyreon Announces First Patient Dosed in Randomized Phase 2 ONT-380 …
With no approved therapy for the treatment of brain metastases, options for this patient population are currently limited,” said Erika Hamilton, M.D., director, Breast and Gynecologic Cancer Research Program, Sarah Cannon Research Institute. “This ... [...]
5
Like
Save
Apremilast relieved psoriatic arthritis symptoms in phase 3 study
At week 16, 93% of patients completed the trial, with comparable rates of completion between the treatment groups and placebo group. Significantly more patients who received 20-mg or 30-mg apremilast achieved an ACR20 response rate, with 28% of ... [...]
1
Like
Save
Apremilast Promising in Phase III for PsA
Treatment of psoriatic arthritis with the oral phosphodiesterase 4 inhibitor apremilast was effective for both the articular and cutaneous manifestations of the disease. Note that the most common adverse events observed during the placebo-controlled ... [...]
3
Like
Save
Sophiris Bio Reports Encouraging Preliminary Data from Phase 2a Proof of …
The ongoing Phase 2a proof of concept study is a single-center, open-label study at University College London, which is well known for the focal treatment of prostate cancer in the UK. In this study, previously obtained multiparametric magnetic ... [...]
6
Like
Save
Lancet Oncology Publishes Results From the Phase 2 TERRAIN Trial of …
The trial enrolled patients with metastatic prostate cancer whose disease progressed despite treatment with a luteinizing hormone-releasing hormone (LHRH) analogue therapy or following surgical castration. The primary endpoint of the trial was PFS ... [...]
1
Like
Save